Literature DB >> 33125301

Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.

Laura Pala1, Fabio Conforti1, Emilia Cocorocchio1, Pierfrancesco Ferrucci1, Martino Tommaso De Pas1, Sara Stucchi1,2, Matteo Repetto3,4, Maristella Saponara1, Paola Queirolo1.   

Abstract

The outbreak of COVID-19 pandemia is a major health worldwide concern. Patients with cancer might have a worse outcome, because of the immunosuppression determined by the tumor itself and anti-cancer treatments, including chemotherapy and radiotherapy. The impact and course of viral infection in patients receiving immunotherapy remains unknown. We report the case of a patient with metastatic melanoma, long responder to anti PD-1 blockade who got infected with Sars CoV-2, recovering without sequelae. A critical review of literature was performed. Limited data available in literature support the possibility to continue the immunotherapy in patients with cancer under control.

Entities:  

Keywords:  COVID-19; Melanoma; anti-PD-1; cancer

Year:  2020        PMID： 33125301     DOI： 10.1080/07357907.2020.1844893

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  6 in total

Review 1.  Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19.

Authors:  M Barnova; A Bobcakova; V Urdova; R Kosturiak; L Kapustova; D Dobrota; M Jesenak
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  Melanomversorgung während eines Jahres Pandemie in Berlin: abnehmende Terminstornierungen trotz zunehmender Besorgnis über COVID-19.

Authors:  Aleksandra Micek; Katharina Diehl; Miriam Teuscher; Marthe-Lisa Schaarschmidt; Bianca Sasama; Jan Ohletz; Guido Burbach; Felix Kiecker; Uwe Hillen; Wolfgang Harth; Wiebke K Peitsch
Journal:  J Dtsch Dermatol Ges       Date:  2022-07       Impact factor: 5.231

3.  Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study.

Authors:  Matilde Sánchez-Conde; Pilar Vizcarra; José Manuel Pérez-García; María Gion; María Pilar Martialay; Javier Taboada; Alberto Alonso-Fernández; Miguel Sampayo-Cordero; Andrea Malfettone; Isabel Tena; Sergio De La Torre; Antonio Llombart-Cussac; Javier Cortés
Journal:  Int J Infect Dis       Date:  2022-08-17       Impact factor: 12.074

4.  Melanoma care during one year pandemic in Berlin: decreasing appointment cancellations despite increasing COVID-19 concern.

Authors:  Aleksandra Micek; Katharina Diehl; Miriam Teuscher; Marthe-Lisa Schaarschmidt; Bianca Sasama; Jan Ohletz; Guido Burbach; Felix Kiecker; Uwe Hillen; Wolfgang Harth; Wiebke K Peitsch
Journal:  J Dtsch Dermatol Ges       Date:  2022-06-06       Impact factor: 5.231

Review 5.  Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.

Authors:  Annoor Awadasseid; Qiang Yin; Yanling Wu; Wen Zhang
Journal:  Biomed Pharmacother       Date:  2021-07-28       Impact factor: 6.529

Review 6.  Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.

Authors:  Tommaso Morelli; Kohei Fujita; Gil Redelman-Sidi; Paul T Elkington
Journal:  Thorax       Date:  2021-10-04       Impact factor: 9.139
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.